Megestrol acetate
- Generic Name
- Megestrol acetate
- Brand Names
- Megace
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4
- CAS Number
- 595-33-5
- Unique Ingredient Identifier
- TJ2M0FR8ES
- Background
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
- Indication
For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
- Associated Conditions
- Anorexia, Cachexia, Inoperable Carcinoma of Breast, Inoperable Endometrial Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Endometrial Carcinoma, Significant, Unexplained Weight Loss, Metastatic Endometrial carcinoma
- Associated Therapies
- Palliative Treatment
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- St. Vincent Medical Center - Los Angeles
- Registration Number
- NCT00002465
- Locations
- 🇺🇸
St. Vincent Medical Center - Los Angeles, Los Angeles, California, United States
Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 40
- Registration Number
- NCT00002680
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
- Conditions
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004912
- Locations
- 🇺🇸
University of Arkansas - Department of Geriatrics, North Little Rock, Arkansas, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Office of David Cella, Evanston, Illinois, United States
Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT00070148
- Locations
- 🇺🇸
CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸Alamance Cancer Center at Alamance Regional Medical Center, Burlington, North Carolina, United States
🇺🇸Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
- Conditions
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00016341
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 70
- Registration Number
- NCT00066248
- Locations
- 🇺🇸
Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸University of Florida Shands Cancer Center, Gainesville, Florida, United States
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
- Conditions
- First Posted Date
- 2003-08-06
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00031785
- Locations
- 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite
- Conditions
- Interventions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 429
- Registration Number
- NCT00031707
- Locations
- 🇨🇦
Queen Elizabeth Hospital, PEI, Charlottetown, Prince Edward Island, Canada
🇨🇦Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
- Conditions
- First Posted Date
- 2003-07-28
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT00006799
- Locations
- 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Conditions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 300
- Registration Number
- NCT00041275
- Locations
- 🇸🇬
Changi General Hospital, Singapore, Singapore
🇮🇩Rumah Sakit Sanglah, Denpasar, Bali, Indonesia
🇲🇲Yangon General Hospital, Yangon, Myanmar
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.